Clinical TrialsSearch results
Number of results: 823
Completed
- A research study of a new medicine NNC0519-0130 in Japanese and non-Japanese men
- type 2 diabetes
- Tsukasaki Nobuaki
- 2023-05-26
Completed
- A RELATIVE AND ABSOLUTE BIOAVAILABILITY STUDY OF AMY109 WITH HEALTHY MALE VOLUNTEERS
- Endometriosis
- Hashimoto Akiko
- 2022-08-27
Completed
- A randomized, participant and investigator-blinded, placebo-controlled, single ascending intravenous and single subcutaneous dose study to assess the safety, tolerability and pharmacokinetics of CMK389 in Japanese healthy participants
- Japanese healthy participants
- Yamada Hiroyuki
- 2022-01-21
Completed
- A Randomized, Active-comparator, Observer-blind, Phase I/II/III Study to Demonstrate the Immunogenicity of a Single Booster Dose of DS-5670a in Adults and Elderly Received a Primary Series of Approved COVID-19 Vaccine
- Prevention of infectious disease by SARS-CoV-2
- Inoguchi Akihiro
- 2021-12-28
Completed
- A prospective study of investigating the efficacy of FOLFIRI plus Aflibercept as a 2nd line therapy after progression during FOLFOXIRI plus Bevacizumab in unrescetable / metastatic colorectal cancer (CRC) patients.
- Colorectal Cancer
- Oki Eiji
- 2019-04-18
Completed
- A PHASE I, TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND IMMUNOGENICITY OF RAY121 IN HEALTHY VOLUNTEERS
- Healthy Volunteer
- Kai Megumi
- 2022-08-04
Completed
- A Phase I Dose Escalation and Food Effect Study of Isotretinoin
- Severe acne vulgaris
- Toida Tsuneyuki
- 2022-11-25
Completed
- A phase I clinical study of KSP-0243
- Healthy Condition
- Shimizu Yoshitaka
- 2021-01-20
Completed
- A Phase 2 study to assess the safety, immunogenicity and recommended dose of DS-5670a in Japanese healthy adults
- Prevention of infectious disease by Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)
- Inoguchi Akihiro
- 2021-10-29
Completed
- A Phase 1/2 study to assess the safety, immunogenicity and recommended dose of DS-5670a in Japanese healthy adults and elderly subjects
- Prevention of COVID-19
- Inoguchi Akihiro
- 2021-03-10